ArticleRadiology case reports2025
Pneumonitis secondary to intravesical Bacillus-Calmette-Guérin (BCG) immunotherapy.
Article in Radiology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intra vesical Bacillus Calmette-Guérin (BCG) instillation therapy is a well-established treatment for superficial bladder cancer, though it can occasionally lead to rare systemic complications. We report the case of a man in his early 80s who developed acute onset dyspnoea after receiving BCG therapy. Clinical evaluation supported by pathology and multi-modal imaging including X-rays, CTs and PET scans led to a diagnosis of BCG-induced pneumonitis, a rare but serious complication. The exact underlying mechanism is still not fully understood and thus no standardized treatment protocol exists. Success has been reported in the literature with the use of anti-tuberculous drugs in combination with steroids. Our patient was successfully treated with anti-tuberculous medication only, for 4 months. This case highlights the importance of maintaining awareness for systemic BCG findings in patients undergoing intra vesical BCG instillations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.